Morgan Stanley initiates coverage on Telix Pharmaceuticals stock with Overweight rating

Morgan Stanley initiated coverage on Telix Pharmaceuticals (ASX:TLX) with an Overweight rating and a price target of AUD25.60, forecasting Illuccix/Gozellix revenue of US$598 million in 2025 and US$690 million in 2026. This positive outlook is largely driven by potential improved prostate cancer imaging reimbursement for Gozellix through CMS transitional pass-through pricing from October 2025, alongside long-term growth opportunities from new formulations and expanded indications. While modest near-term earnings are anticipated, significant margin improvements and free cash flow generation are projected from fiscal years 2029-2030, supporting a base case valuation of AUD26.30 per share.

Analysis

Morgan Stanley has initiated coverage on Telix Pharmaceuticals Ltd (ASX:TLX) with a bullish outlook, assigning an Overweight rating and an AUD25.60 price target. The firm's positive thesis is underpinned by specific revenue forecasts for Telix's prostate cancer imaging agent, Illuccix/Gozellix, projecting US$598 million in 2025 and US$690 million in 2026. A key catalyst for this growth is the potential for improved reimbursement through CMS transitional pass-through pricing for Gozellix, anticipated to begin on October 1, 2025. While near-term earnings are expected to be modest following the 1H25 results, the investment bank projects a significant inflection in profitability, with substantial margin improvements and free cash flow generation from fiscal years 2029-2030. The valuation is notably split between current and future assets; Morgan Stanley's base case of AUD26.30 per share comprises AUD14.30 from approved Precision Medicine products and a risk-weighted AUD12.00 from Phase 3 therapeutic candidates, highlighting a dependency on pipeline execution for full value realization.

Key Decisions for Investors

• Investors with a long-term horizon should consider the Overweight rating a strong positive signal, supported by specific revenue forecasts and a clear catalyst in the form of potential CMS reimbursement changes in late 2025.
• The primary factor to monitor is the confirmation of CMS pass-through pricing for Gozellix around October 2025, as this is a critical component of the near-to-medium term growth thesis.
• It is important to recognize the investment timeline, as significant free cash flow generation and margin expansion are not anticipated until 2029-2030, requiring patience through potentially modest near-term earnings reports.
• Investors must weigh the risk profile, noting that nearly half of Morgan Stanley's base case valuation is attributed to risk-weighted Phase 3 pipeline assets, which carry inherent clinical and regulatory uncertainties.